Loss of the transcriptional regulator MEIS2 is not only associated with recurrence and worse survival in PCa patients [36], but is also associated with the development of castration-resistant prostate cancer due to its inhibition resulting in constitutive activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling [37]. The gene discussed is MEIS2; the disease is posterior cortical atrophy.